At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RXRX Recursion Pharmaceuticals, Inc.
Closed 10-08 16:00:00 EDT
3.95
-0.32
-7.49%
盘后3.94
-0.01-0.25%
19:59 EDT
High4.20Low3.79Vol30.90M
Open4.19D1 Closing4.27Amplitude9.60%
Mkt Cap2.11BTradable Cap2.06BTotal Shares535.00M
T/O121.37MT/O Rate5.92%Tradable Shares522.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.08% in Regular Trading, Insider Selling and Amended Tempus AI Agreement Weigh on Sentiment
Market Focus  ·  10-08 22:53
Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.08% in Regular Trading, Insider Selling and Amended Tempus AI Agreement Weigh on Sentiment
Top Recursion Pharma Insider Makes a Major Move With His Shares
TIPRANKS  ·  10-08 10:02
Top Recursion Pharma Insider Makes a Major Move With His Shares
Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today
TIPRANKS  ·  10-08 08:05
Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today
Recursion Director Robert Hershberg Sells 25,000 Common Shares for $125,000
Reuters  ·  10-08 06:08
Recursion Director Robert Hershberg Sells 25,000 Common Shares for $125,000
Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.21% in Regular Trading, Tempus Data License Amendment Spurs Market Divergence
Market Focus  ·  10-08 01:31
Movement Alert｜Recursion Pharmaceuticals, Inc. Falls 8.21% in Regular Trading, Tempus Data License Amendment Spurs Market Divergence
Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today
TIPRANKS  ·  10-06
Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today
NASD Most Active Issues
Dow Jones  ·  10-06
NASD Most Active Issues
Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?
Simply Wall St.  ·  10-03
Could Tempus RNA License Alter The Investment Case For Recursion Pharmaceuticals (RXRX)?
One Weekend, Thousands Of Compounds: Inside Microsoft's New AI Biology Model
AI Industry Frontlines  ·  10-03
One Weekend, Thousands Of Compounds: Inside Microsoft's New AI Biology Model
Novartis Bets $7.8 Billion On MRNA Beyond Vaccines
Options & Short Sell  ·  10-02
Novartis Bets $7.8 Billion On MRNA Beyond Vaccines
From Exoskeletons to AI: ChronoScale's Billion-Dollar Pivot
Tech News Roundup  ·  10-02
From Exoskeletons to AI: ChronoScale's Billion-Dollar Pivot
Recursion Licenses TxFM RNA Foundation Model to Tempus AI for Oncology Use in USD 12 Million Deal
Reuters  ·  09-22
Recursion Licenses TxFM RNA Foundation Model to Tempus AI for Oncology Use in USD 12 Million Deal
Tempus Extends Data Licensing Partnership with Recursion Through November 2029
Reuters  ·  09-22
Tempus Extends Data Licensing Partnership with Recursion Through November 2029
Tempus AI, Recursion Extend Data License, Amend Fee Structure
MT Newswires Live  ·  09-21
Tempus AI, Recursion Extend Data License, Amend Fee Structure
Recursion, Tempus Expand AI and RNA Collaboration Agreements
TIPRANKS  ·  09-21
Recursion, Tempus Expand AI and RNA Collaboration Agreements
Tempus AI, Recursion extend data license agreement, enter new license agreement
TIPRANKS  ·  09-21
Tempus AI, Recursion extend data license agreement, enter new license agreement
Tempus AI, - Recursion Grants Tempus Non-Exclusive Worldwide License to Rna Sequencing Model Txfm
THOMSON REUTERS  ·  09-21
Tempus AI, - Recursion Grants Tempus Non-Exclusive Worldwide License to Rna Sequencing Model Txfm
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s Rna Foundation Model
THOMSON REUTERS  ·  09-21
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s Rna Foundation Model
Tempus AI, -Co and Recursion Extend Data Partnership Through November 2029
THOMSON REUTERS  ·  09-21
Tempus AI, -Co and Recursion Extend Data Partnership Through November 2029
Recursion Pharmaceuticals - Enters Amendment to Master Agreement with Tempus on Sept 15, 2026 - SEC Filing
THOMSON REUTERS  ·  09-21
Recursion Pharmaceuticals - Enters Amendment to Master Agreement with Tempus on Sept 15, 2026 - SEC Filing

Introduction

Company Name.
Recursion Pharmaceuticals, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Issue price:
--